Partner & exhibitor packages now open for AusBiotech 2012
28 February, 2012 by AusBiotechPartnership and exhibition packages are now available for the AusBiotech 2012 national conference to be held in Melbourne, Victoria from 30 October to 2 November 2012.
Phylogica wins US peptide patent
27 February, 2012 by Dylan Bushell-EmblingPerth-based Phylogica (ASX:PYC) has received a US patent for one of its Phylomer library of peptides with potential drug development leads.
Working group on promotion of therapeutic products
23 February, 2012 by AusBiotechKey industry stakeholders have been debating whether or not companies should prescribe to a harmonised code of conduct to achieve TGA registration.
Start-up Vitality signs APAC distribution deals
22 February, 2012 by Dylan Bushell-EmblingVitality Devices, a new Australian company founded to commercialise medical devices in Asia-Pacific, has signed its first two distribution deals.
Gene patents challenged in court
22 February, 2012 by Dylan Bushell-EmblingIn the middle of the patent fight over the BRCA1 gene mutation, Genetic Technologies (ASX:GTG) announced a new settlement in the rash of infringement suits covering its non-coding DNA patent.
AusBiotech international investment showcase events in Hong Kong and New York
21 February, 2012 by AusBiotechAusBiotech is calling for expressions of interest to participate in two international showcase events in Hong Kong and New York.
Genetic Technologies gains access to full US market for BREVAGen
17 February, 2012 by Dylan Bushell-EmblingGenetic Technologies' (ASX:GTG) Victorian lab has received US certification that will enable it to launch its BREVAGen cancer test in all 50 US states.
Bionomics seeks patent for Alzheimer's treatment
17 February, 2012 by Dylan Bushell-EmblingSouth Australia's Bionomics (ASX:BNO) is pursuing an international patent application for a method of improving memory in patients with Alzheimer's and other neurodegenerative diseases.
Lorne 2012: The war on superbugs
16 February, 2012 by Fiona WylieLorne Infection & Immunity: Resistance to antibiotics is an increasingly serious threat to human health worldwide. Now, a new Wellcome Trust-funded partnership with scientists in Queensland is fighting back.
Heavy hitters in business development arriving
16 February, 2012 by AusBiotechThe biotech industry’s heavy hitters in business development are about to gather in Queensland for the annual dedicated forum for business development professionals.
Phosphagenics' redesigned pain patch shows improved results
16 February, 2012 by Dylan Bushell-EmblingA trial of Phosphagenics' (ASX:POH) new TPM/oxycodone patch design proves that the redesign improves drug delivery by 4.5 times the original prototype version.
William Ardrey to face fraud charges in WA
15 February, 2012 by Tim DeanFormer CEO of Avantogen, Dr William Ardrey, is to appear in Perth Magistrates Court this Friday on 19 counts of fraud.
Prima BioMed files for NASDAQ listing
14 February, 2012 by Dylan Bushell-EmblingSydney-based Prima BioMed (ASX:PRR) has filed a registration for a dual-listing on the NASDAQ exchange, a move first announced in 2010.
AusBiotech supporting industry employment
14 February, 2012 by AusBiotechAusBiotech has relaunched the employment section on its high-traffic website, giving members the opportunity to list vacancies free and qualified industry professionals access to the latest list of industry jobs.
LBT royalty deal lower than hoped
13 February, 2012 by Dylan Bushell-EmblingLab technology company LBT Innovations (ASX:LBT) has negotiated a less-than-hoped-for minimum royalty deal with licensee bioMérieux worth US$600,000 per year.
